Enlimomab

Drug Profile

Enlimomab

Alternative Names: BIRR 0001; BIRR 1; Murine anti-CD54 monoclonal antibody; Murine anti-ICAM-1 monoclonal antibody; R6 5 D6; R6.5; RR1; RR1/1

Latest Information Update: 18 Dec 2001

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Intercellular adhesion molecule 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Autoimmune disorders; Burns; Diabetes mellitus; Graft-versus-host disease; Intracranial thrombosis; Liver transplant rejection; Myocardial ischaemia; Renal transplant rejection; Rheumatoid arthritis; Stroke

Most Recent Events

  • 18 Dec 2001 A study has been added to the adverse events and Neurological Disorders therapeutic trials sections
  • 10 May 1999 Results of a clinical study were added to the adverse events and therapeutic trials sections
  • 03 Feb 1999 A study has been added to the Neurological disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top